Using dSTORM, we showed that treatment of HER2-expressing breast cancer cells (SK-BR-3) with zanidatamab induced the formation of large HER2 clusters to a much greater extent than trastuzumab, pertuzumab, or tras + pert treatment. The gene discussed is ERBB2; the disease is breast cancer.